Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects
Bitget2026/09/30 20:01- Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects.
- Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment.
- The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cryptocurrencies Turn Higher as Equities Change Course -- Market Talk
U.S. homebuilder confidence unexpectedly falls to a 14-year low, hit by both high interest rates and cost pressures
The Housing Market Index, jointly released by the National Association of Home Builders (NAHB) and Wells Fargo, fell by 3 points this month to 29, the lowest level since June 2012 and below the market expectation of 31. The sales sub-index dropped to 33, also a 14-year low; the index for expected sales over the next six months declined to its weakest level since November 2022; the index measuring potential buyer traffic fell to its lowest point since the onset of the COVID-19 pandemic.
Crypto prices
More
